

Press Release

VanEck provides access to the two most important trends in healthcare with new ETF

- **The VanEck Genomics and Healthcare Innovators UCITS ETF complements VanEck's line-up of impact products**
- **Genomics offers potential for treating cancer or diseases associated with ageing populations**
- **Pandemic-related demand for remote medical care solutions continues to drive healthcare digitalisation**

London, 7 September 2022 – Asset manager VanEck lists the *VanEck Genomics and Healthcare Innovators UCITS ETF* on the London Stock Exchange and the German Xetra Stock Exchange. The new ETF allows investors to invest in a combination of two of the most important themes in the healthcare industry: Genomics and digitalisation.

Genomics is a branch of science that studies the interaction between genes and gene products. “Genetic treatments, which have once been considered experimental and expensive, are becoming more affordable and common,” explains Martijn Rozemuller, CEO at VanEck Europe. The genomics industry, which targets prominent topics such as the treatment of cancer, ageing and congenital diseases, is still in the early stages of its development and thus still offers great potential.

In addition, the healthcare industry, which was lagging behind in adopting IT solutions before the pandemic, has seen a surge in digitalisation over the past two years. “Face-to-face meetings with patients were no longer an option, and digital solutions were able to prove their everyday viability in the healthcare industry,” Rozemuller explains. “So far, however, digital solutions are still far from widespread. We assume that there is still room for further growth.”

Companies must generate 50 per cent of their revenue from a list of eight topics

The ETF follows the MVIS Global Future Healthcare ESG Index, which tracks the performance of companies contributing to genetic and/or digital applications in healthcare, adding to the family of impact ETFs VanEck offers in Europe. From inception, companies that generate at least 50 per cent of their sales in the following areas are eligible for inclusion in the index:

- Health therapies based on the targeted modification of the genetic code of cells or using mRNA
- Technology platforms that enable the development of therapies for healthcare based on genetics
- Laboratory equipment or services used to test, code, or develop genetics-based health therapies
- Software to facilitate online medical consultations
- Online pharmacies
- Software for the management of medical practices and/or patient records

- Ambulatory medical IoT devices

The accumulating VanEck Genomics and Healthcare Innovators UCITS ETF has a total expense ratio (TER) of 0.35 per cent and is rebalanced semi-annually.

Equity market risk: The prices of securities in the fund are subject to the risks inherent in investing in the securities market, including general economic conditions and sudden and unpredictable price drops. An investment in the fund may result in losses. Industry or sector concentration risk: The assets of the fund may be concentrated in one or more sectors or industries. The fund may be subject to the risk that political, economic or other conditions adversely affecting the relevant sectors or industries may adversely affect the performance of the fund to a greater extent than if the fund's assets were invested in a wider variety of sectors and industries.

ETF	VanEck Genomics and Healthcare Innovators UCITS ETF
ISIN Code	IE000B9PQW54
Ticker LSE USD / GBP	CURE / CURG
Ticker Xetra	CURE
Investment manager	VanEck Asset Management B.V.
Index provider	Market Vector Indexes GmbH
Base currency	US Dollar
Fund domicile	Ireland
Reconstitution	Semi-annually
Product structure	Physical (full replication)
Income Treatment	Reinvestment
Launch date	2 September 2022
Total expense ratio (TER)	0.35% p.a.

Contact:

Henning Mönster / Miriam Wolschon
 public imaging GmbH
 Tel.: +49 (0)40 401999-156 / -155
 E-mail: vaneck@publicimaging.de

Guy Taylor
 Peregrine Communications
 Tel.: +44 (0) 20 3040 0867
 E-Mail: vaneck@peregrinecommunications.com



About VanEck

VanEck has a history of looking beyond the financial markets to identify trends that are likely to create impactful investment opportunities. As of August 30, 2022, VanEck managed approximately 69 US Dollar billion in assets, including mutual funds, ETFs and institutional accounts.

With more than 90 ETFs globally, the asset manager offers a comprehensive portfolio covering numerous sectors, asset classes and smart beta strategies. VanEck was one of the first asset managers to offer investors access to international markets. The objective has always been to identify new trends and asset classes – such as Gold Investments (1968), Emerging Markets (1993) and ETFs (2006), which have shaped the investment industry to this day.

VanEck is headquartered in New York City and has offices in Frankfurt (Germany), Pfaeffikon (Switzerland), Amsterdam (Netherlands), Sydney (Australia) and Shanghai (China).

Important Disclosures

For informational and advertising purposes only.

This information originates from VanEck (Europe) GmbH which has been appointed as distributor of VanEck products in Europe by the Management Company VanEck Asset Management B.V., incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM). VanEck (Europe) GmbH with registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, is a financial services provider regulated by the Federal Financial Supervisory Authority in Germany (BaFin). The information is intended only to provide general and preliminary information to investors and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together “VanEck”) assume no liability with regards to any investment, divestment or retention decision taken by the investor on the basis of this information. The views and opinions expressed are those of the author(s) but not necessarily those of VanEck. Opinions are current as of the publication date and are subject to change with market conditions. Certain statements contained herein may constitute projections, forecasts and other forward looking statements, which do not reflect actual results. Information provided by third party sources are believed to be reliable and have not been independently verified for accuracy or completeness and cannot be guaranteed. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index.

VanEck Asset Management B.V., the management company of VanEck Genomics and Healthcare Innovators UCITS ETF (the “ETF”), a sub-fund of VanEck UCITS ETFs plc, is a UCITS management company incorporated under Dutch law registered with the Dutch Authority for the Financial Markets (AFM). The ETF is registered with the Central Bank of Ireland and tracks an equity index. The value of the ETF’s assets may fluctuate heavily as a result of the investment strategy. If the underlying index falls in value, the ETF will also lose value.

Investors must read the sales prospectus and key investor information before investing in a fund. These are available in English and the KIIDs in certain other languages as applicable and can be obtained free of charge at www.vaneck.com, from the local information agent Computershare Investor Services PLC or from the Management Company.

MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH (“MarketVector”), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Genomics and Healthcare Innovators UCITS ETF is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the Fund.

All performance information is historical and is no guarantee of future results. Investing is subject to risk, including the possible loss of principal. You must read the Prospectus and KIID before investing in a fund.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

© VanEck (Europe) GmbH